Lexeo Therapeutics (LXEO) Announces Proposed IPO

Lexeo Therapeutics (NASDAQ: LXEO) has filed for a proposed IPO.

From the filing: "We are a clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. By taking aim at the underlying genetic cause of the devastating diseases we target, we seek to create substantial positive impact and reduce the overwhelming burdens placed on people receiving treatment, their caregivers, and healthcare systems. Our current pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to our genetic medicine approach. "

J.P. Morgan, Leerink Partners, Stifel and RBC Capital Markets will serve as lead underwriters.

You May Also Be Interested In

• Braveheart Bio raises $439.9M in upsized Nasdaq IPO
• Nscale Touts $51 Billion In Contracts, Targets September US IPO - Bloomberg
• BlossomHill Therapeutics prices $150M IPO at $16 per share